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Case Report: 
The Alteration of Clinical and Laboratory Signs and 
Symptoms of COVID-19 in Re-infection: A Case Report
Background: Patients can be carriers of the virus for a long time or become re-infected or re-
infected following the use of immunosuppressive drugs. Clinical manifestations in patients are 
very diverse and can range from asymptomatic to severe illness with death. Patients may also 
present with manifestations such as coagulation disorders, cardiac dysfunction and arrhythmias, 
acute coronary syndrome, kidney injury, liver injury, Refer to diabetic hyperglycemia and 
ketoacidosis. This is an essential point in the prevention of Coronavirus Disease 19 (COVID-19).
Case Presentation: We reported a case in which the Polymerase Chain Reaction (PCR) test 
was positive after re-negative after 5 months. Moreover, the patient presented different and 
more severe symptoms than the previous infection, as the genetic difference between the strains 
increased over time.
Conclusion: As a result, immunization may become more complicated, and different clinical 
pictures occur; thus, this condition can challenge vaccine immunization. 
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1. Introduction
oronavirus Disease 19 (COVID-19) is the 
largest and most severe epidemic since the 
1918 flu [1]. The appearance of this dis-
ease has created unprecedented challeng-
es for public health [2]. The coronavirus 
is transmitted mainly through respiratory 
droplets and close contact with others [3]. Clinical mani-
festations in infected patients are very diverse and can 
range from asymptomatic disease to a severe condition 
and death [4]. In most cases, the virus causes pulmonary 
pneumonia [5]. Re-infection may occur following some 
immunosuppressive therapy or in the elderly [6]. Studies 
have also suggested that patients with defective immune 
systems are more prone to reinfection [7]. Despite evi-
dence of an acquired immune response after coronavirus 
infection, studies have indicated that patients with mild 
symptoms and a weaker immune response with reduced 
antibody levels, after 2 to 3 months, become re-infected 
[8]. Eighty species of viral genotypes have been identi-
fied. Moreover, as genetic differences between strains in-
crease over time, cross-breeding immunity may become 
more difficult [9]. According to reports, in the case of a 
pandemic with other viruses of the coronavirus family, 
immunity was established for ≥2 years, i.e., not the case 
with COVID-19 [10].
2. Case Peresentation
The patient, a 54-year-old man, fell to the ground on 
April 10, 2020, following dizziness. Besides, he encoun-
tered a forehead lesion, after which he was admitted to 
the hospital emergency room. The patient lived in a dis-
abled nursing home and reported no history of diseases 
or the use of drugs (Table 1).
Due to the positive D-dimer and o2sat of <93, the patient 
underwent a lung scan without contrast (Figure 1-A).
Considering the positive PCR test data, the patient 
was admitted to the isolation ward with a diagnosis of 
COVID-19. The patient was treated with enoxaparin 40 
mg daily, vitamin C 1gr per day, ceftriaxone 1gr every 
12 hours, hydroxychloroquine 200 mg every 12 hours, 
azithromycin 250 mg daily, and atorvastatin 40 mg daily. 
In the first 3 days of hospitalization, he received 2 liters 
of nasal oxygen per minute. The patient was reported to 
have >95% oxygen saturation without oxygen therapy. 
On April 17, due to the improvement of clinical symp-
toms, PCR tests and scans were performed to con
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firm the existence of suitable conditions for discharge. 
Furthermore, after presenting a negative PCR test and 
the improvement of lung condition, the patient was dis-
charged for re-scan (Figure 1-B).
On the 20th of August 2020, the patient has referred to 
the emergency room again due to fever and chills, short-
ness of breath, and body pain. He was tachypnea; in ex-
amining the patient’s vital signs presented 84% o2sat, 




Figure 1. Lung scan 
A: Lung scan at the time of the patient's first hospitalization; B: Scan the patient's lungs at discharge; C: Scan 
the patient at the time of readmission
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again (Figure 1-C). According to positive PCR and tests 
(Table 1), the patient was admitted to the isolation ward. 
Next, the patient received oxygen with a nasal catheter 
4 liters per minute and was treated with ceftriaxone, in-
terferon beta1b, enoxaparin, methylprednisolone, and 
atazanavir. Moreover, the patient was discharged after 
7 days with the improvement of clinical symptoms and 
PCR test before discharge according to hospital protocol 
and negative PCR test.
3. Discussion
The possibility of recurrence of COVID-19 is a major 
public health concern. This is because it can lead to an 
increase in the prevalence of the disease in the commu-
nity [11]. The presented patient was referred for the sec-
ond time after 5 months with different initial symptoms. 
The patient presented at the first visit without respiratory 
symptoms and with neurological symptoms. Besides, 
pulmonary involvement was accidentally diagnosed. 
The patient was discharged with a negative test and con-
trolled scan. In the second pulmonary involvement, most 
of the PCR test was positive again and the patient pre-
sented respiratory symptoms. Therefore, infection with 
coronavirus cannot guarantee immunity for subsequent 
infections [12]; predisposing factors for re-infection can 
be treating the first course of the disease [6]; PCR test-
ing of the throat to ensure that the virus is cleared. This 
is also challenging and may provide false-negative re-
sults, which may require two samples to be taken from 
two different parts (throat & stool) for two consecutive 
days [9]. The patient may also be exposed to a higher 
rate of the virus in the second infection, or, similar to 
that in dengue fever, antibodies in the blood from the 
previous infection may exacerbate the symptoms in the 
new infection [13]. Additionally, ineffective control of 
viral infection may lead to the replication of the virus 
after the cross-sectional suppression of symptoms. It 
is unclear whether all patients provide a protective re-
sponse; and if so, the duration of this response remains 
unrecognized [14]. Inflammation is caused by an inap-
propriate immune response [6]. The patient presented 
more severe symptoms in the readmission, compared to 
the initial case; such a case can raise questions about the 
effects of infection severity on the immune response and 
host susceptibility, which can have critical epidemiologi-
cal consequences [15]. The change in the patient’s initial 
symptoms of re-infection may be due to infection with a 
new strain of the virus [16].
4. Conclusion
We reported a case in which the Polymerase Chain Re-
action (PCR) test was positive after re-negative after 5 
months. Moreover, the patient presented different and 
more severe symptoms than the previous infection, as 
the genetic difference between the strains increased over 
time. As a result, immunization may become more com-
plicated, and different clinical pictures occur; thus, this 
condition can challenge vaccine immunization.
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